joint product development agreementJoint Product Development Agreement • May 5th, 2020 • England and Wales
THIS JOINT PRODUCT DEVELOPMENT AGREEMENT (“Agreement”), effective as of the 17th day of June, 2015 (“Effective Date”), is made and entered into by and between CELLECT BIOMED LTD., an Israeli corporation with its principal office located at 10 Hataas Street, Kfar Saba, Israel (“Cellect”), and ENTEGRIS, INC., a Delaware corporation with its principal office located at 129 Concord Road Billerica, MA 01821 (“Entegris”). Each of Cellect and Entegris are sometimes hereinafter referred to as a “Party” and collectively as the “Parties”.
JOINT PRODUCT DEVELOPMENT AGREEMENTJoint Product Development Agreement • July 16th, 2010 • Corgenix Medical Corp/Co • In vitro & in vivo diagnostic substances • Colorado
This Joint Product Development Agreement (“Agreement”) is made and entered into on this 16th day of July, 2010 (“Effective Date”), by and between Corgenix Medical Corporation, a Nevada corporation (“Corgenix”), with its principal place of business at 11575 Main Street, Suite 400, Broomfield, Colorado 80020, and Financière Elitech SAS, a société par actions simplifiée organized under the laws of France (“Elitech”), with its principal place of business at 12-12bis, rue Jean Jaurès, 92800 Puteaux, France. Corgenix and Elitech are sometimes referred to in this agreement individually as a “Party” and, collectively, as the “Parties.”
EXHIBIT 10.1 JOINT PRODUCT DEVELOPMENT AGREEMENT (Applied Voice Recognition, Inc. and Voice It Worldwide, Inc.) THIS JOINT PRODUCT DEVELOPMENT AGREEMENT (this "Agreement") is entered into as of December 31, 1997 (the "Effective Date"), by and between...Joint Product Development Agreement • April 15th, 1998 • Applied Voice Recognition Inc /De/ • Blank checks • Texas
FIRST AMENDED AND RESTATED JOINT PRODUCT DEVELOPMENT AGREEMENTJoint Product Development Agreement • August 2nd, 2011 • Corgenix Medical Corp/Co • In vitro & in vivo diagnostic substances • Colorado
This First Amended and Restated Joint Product Development Agreement (“Agreement”) is made and entered into on this 28th day of July, 2011 (“Effective Date”), by and among Corgenix Medical Corporation, a Nevada corporation (“Corgenix”), with its principal place of business at 11575 Main Street, Suite 400, Broomfield, Colorado 80020, Financière Elitech SAS, a société par actions simplifiée organized under the laws of France (“Elitech”), with its principal place of business at 12-12bis, rue Jean Jaurès, 92800 Puteaux, France, and Wescor, Inc., a Utah corporation (“Wescor”), with its principal place of business at 370 West 1700 South, Logan, Utah 84321. Each of Corgenix, Elitech and Wescor are sometimes referred to in this agreement individually as a “Party” and, collectively, as the “Parties.”
